Miranova (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol acts as an estrogen agonist, stabilizing the endometrial lining, while levonorgestrel is a progestogen that suppresses the mid‑cycle luteinizing hormone surge, preventing ovulation. Together they thicken cervical mucus and create endometrial changes that make implantation unlikely.

The dosing regimen is set by the prescribing clinician. Miranova is typically supplied as a pack of active tablets followed by a placebo week, but the exact schedule, including any missed‑dose instructions, must be individualized by the healthcare professional.

Miranova is contraindicated during pregnancy; women who become pregnant should discontinue use immediately. Limited data exist for lactating women, and the product is generally not recommended while breastfeeding unless the benefits outweigh potential risks, as determined by a physician.

To order Miranova, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Miranova contains the standard dose range of ethinylestradiol and levonorgestrel found in many combined oral contraceptives, offering comparable efficacy for pregnancy prevention. Differences among products usually relate to hormone dose, pill regimen (21‑day vs 28‑day), and specific brand formulations, which may affect side‑effect profiles.

Miranova tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Miranova is taken orally, once daily, with a glass of water. It is usually recommended to take the tablet at the same time each day to maintain consistent hormone levels. If a dose is missed, follow the specific missed‑dose instructions provided by the prescriber.

The most serious risks include venous or arterial thromboembolism (such as deep‑vein thrombosis, pulmonary embolism, stroke, or myocardial infarction), severe hypertension, liver disorders, and rare allergic reactions. Patients should seek immediate medical attention if they experience symptoms like unexplained leg pain, chest pain, severe headache, or visual changes.

Miranova should not be used by women with a history of thromboembolic disease, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It is also contraindicated in smokers over 35 years of age and in individuals taking interacting medications that significantly reduce contraceptive efficacy.